OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

OBI Pharma | September 14, 2020

OBI Pharma, Inc, a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 (anti-Globo H targeted ADC) at the World ADC Digital Scientific meeting on Sept 16, 2020. The scientific presentation titled, "A Novel Globo H-targeting Antibody-drug Conjugate: OBI 999" with a follow-up live discussion and question session will be led by Ming-Tain Lai, PhD. Chief Scientific Officer at OBI Pharma. The presentation will highlight the results from pre-clinical studies of OBI Pharma's first-in-class anti-Globo H antibody drug conjugate (OBI-999), including animal efficacy and safety data, supporting the ongoing Phase 1/2 human study ongoing at the MD Anderson Cancer Center in Houston, TX (USA).

Spotlight

CRCs are the main liaison between investigators and study
participants, and between the site and the sponsor; they also manage the study activity of clinical sites.

Spotlight

CRCs are the main liaison between investigators and study
participants, and between the site and the sponsor; they also manage the study activity of clinical sites.

Related News

PHARMA TECH

Pfizer, BioNTech COVID-19 vaccine works in more contagious coronavirus variants

Pfizer | January 11, 2021

Newly emerged variants of the novel coronavirus have sparked a key question: Will existing COVID-19 vaccines be less effective against them? But scientists have preliminary data showing that may not be the case, at least for Pfizer and BioNTech’s shot. Researchers from the University of Texas and Pfizer found that, in lab dishes, the vaccine was able to neutralize an engineered version of a variant, which bears an N501Y mutation in its spike protein. The finding was published in bioRxiv and hasn’t been peer-reviewed. Variants of coronavirus with this mutation were first discovered in the U.K. and South Africa and immediately grabbed global attention because they are more contagious. Currently available COVID vaccines—including Pfizer and BioNTech’s Comirnaty, or BNT162b2—target the spike protein of SARS-CoV-2, the coronavirus behind COVID-19. The N501Y mutation improves the ability of the virus’ spike protein to bind to its receptor on human cells, making it easier to gain entry for infection. To test whether Comirnaty worked against the mutation, the scientists collected antibodies from 20 vaccinated trial participants and compared their ability to kill off the engineered virus with the N501Y mutation to their ability to neutralize the strain on which Pfizer and BioNTech based Comirnaty.

Read More

RESEARCH

IDBS Launches Polar™ in a New Product Category That Aims to Streamline and Speed up Biopharmaceutical Development

IDBS | December 07, 2020

IDBS, a product informatics arrangement supplier for biotech and pharma, today reported the dispatch of Polar™, building up another item classification, BioPharma Lifecycle Management (BPLM), pointed toward smoothing out medication advancement and assembling in biopharma research. The advancement of biologics is a unique cycle and the individuals who are best should have the option to adjust to changes in cycle or innovation quickly. IDBS information has discovered that without compelling BPLM, the advancement of a biologic can take as long as three years longer than it should, which impacts the two patients and an organization's primary concern. Despite the fact that biopharma organizations perceive the requirement for proficiency, quality and information honesty, most are as yet losing time to paper records, Excel and other specially appointed frameworks that defer results and endanger measure understanding and quality. Without more productive frameworks, organizations will keep on creating irreproducible outcomes, which prompts rehashed work, inability to separate experiences and postpones development. "Putting up a medication for sale to the public is an unpredictable cycle which proceeds with post-commercialization," said Umay Saplakoglu, Chief Digital Officer at Cytiva. "A significant test today is that information that is created all through the periods of disclosure doesn't generally get moved and rather exists in storehouses – in hardware, in somebody's scratch pad or in an information base. There are no communitarian stages where you can dissect the information and draw experiences from it. This remaining parts probably the greatest test confronting industry today." Polar™ is intended to be quickly sent to explain work process, measure quality, joint effort and information investigation challenges that have pained presently accessible programming arrangements including LIMS and ELN. It will decrease manual information preparing and record, prompting less human mistakes and improved generally speaking precision, and incorporates complete pursuit capacities that help clients find what they are searching for, diminishing the need to pointlessly copy measures. Besides, by making a profoundly contextualized information spine that underpins the entire improvement lifecycle, Polar™ offers out-of-the-crate understanding and investigation, assisting organizations with understanding the advantages of demonstrating and reproduction, helping drive development and decrease time-to-showcase. Polar™, will empower organizations to all the more viably explore the complexities and failures of the medication advancement lifecycle, while receiving the groundbreaking rewards that come from a well curated cycle and quality information spine.

Read More

PHARMA TECH

Capacity and Citeline Connect Partner for AI-Powered Clinical Trial Recruitment Experience

Capacity | August 12, 2021

Capacity, an AI-powered support automation platform, today announces its partnership with Citeline Connect, the all-in-one clinical trial recruitment platform developed by Informa Pharma Intelligence. The companies partnered to launch Moderna's clinical trial recruitment website with an AI-powered chatbot to provide a comprehensive experience for potential study participants. This partnership enables customers like Moderna to create engaging clinical trial recruitment websites. With the power of Capacity's chatbot and support automation software alongside Citeline Connect technology, users are able to actively complete registration and pre-screening through an easy-to-use interface. "Our work with Citeline Connect is reflective of our ultimate goal at Capacity, leveraging a company's existing knowledge base with support automation to help teams do their best work," said David Karandish, CEO of Capacity. "As we see relief from the COVID-19 pandemic on the horizon, there is still a way to go before we are in the clear. In working with Citeline Connect, we're honored to have the opportunity to provide helpful technology for healthcare providers, researchers, and patients." Capacity and Citeline Connect's first-of-its-kind work will enhance the patient experience. With user-friendly technology, Capacity's chatbot provides an expansive knowledge-base and user-friendly solution. "We are proud of our ability to create more opportunities for the public to engage with important clinical trials," said Chris Venezia, chief commercial officer at Citeline Connect. "Working with Capacity is a no-brainer to provide an extensive solution that meets the needs of potential patients and the clinical trial sponsors. They make it easy for both potential and current study participants to ask questions, find clinical trial information, and begin their study enrollment journey" This partnership comes on the heels of Capacity's growth and recognition across industries. Capacity was recognized as the "Adaptive Learning Innovation of the Year" in the 2021 EdTech Breakthrough Awards, as a "Tech 100 Mortgage Winner" by HousingWire, and was a 2021 FinTech award winner for the "Most Innovative Financial Services Machine Learning UI Solution - North America" by Wealth and Finance International. Capacity was also recognized by Knowledge Management World as one of the top 100 companies that matter most in knowledge management, and secured $12M in Series C funding late last year to continue innovating solutions for its customers. About Capacity Capacity is an AI-powered support automation platform that connects your entire tech stack to answer questions, automate repetitive support tasks, and build solutions to any business challenge. Capacity was founded in 2017 by David Karandish and Chris Sims, and is part of the Equity.com incubator.

Read More